Common Contracts
4 similar null contracts by Eleven Biotherapeutics, Inc., Sesen Bio, Inc.
Personal & ConfidentialSesen Bio, Inc. • August 13th, 2018 • Pharmaceutical preparations
It is my pleasure to offer you the position of President and Chief Executive Officer for Sesen Bio, Inc. (“the Company” or “Sesen Bio”) reporting to the Board of Directors (the “Board”). This letter summarizes important details about your employment, should you accept this offer. This letter agreement shall be effective on the date hereof.
January 23, 2018 Personal & Confidential Richard Fitzgerald Dear Richard:Eleven Biotherapeutics, Inc. • January 25th, 2018 • Pharmaceutical preparations
It is my pleasure to offer you the position of Chief Financial Officer for Eleven Biotherapeutics, Inc. (the “Company” or “Eleven Bio”) reporting to Stephen Hurly, President and CEO. This letter agreement summarizes important details about your employment, should you accept this offer. This letter agreement shall be effective as of the last date of execution by the parties hereto (the “Effective Date”).
September 20, 2016 Personal & Confidential Stephen Hurly Haddonfield, NJ 08033 Dear Stephen:Eleven Biotherapeutics, Inc. • September 21st, 2016 • Pharmaceutical preparations
It is my pleasure to offer you the position of President and Chief Executive Officer for Eleven Biotherapeutics, Inc. (“the Company” or “Eleven Bio”) reporting to the Board of Directors (the “Board”). This letter summarizes important details about your employment, should you accept this offer. This letter agreement shall be effective only upon the date of the closing (such closing date, the “Effective Date”) of the acquisition by the Company of Viventia Bio Inc. (“Viventia”) pursuant to a Share Purchase Agreement (the “Agreement”), by and among the Company, Viventia, the shareholders of Viventia named on the signature pages thereto and, for certain limited purposes, Clairmark Investments Ltd, pursuant to which Agreement, the Company will acquire all of the outstanding equity interests in Viventia and Viventia will become a wholly-owned subsidiary of the Company (the “Transaction”). If the Transaction does not occur by September 23, 2016, this letter agreement shall be null and void.
September 20, 2016 Personal & Confidential Arthur P. DeCillis, M.D. Madison, CT 06443 Dear Arthur:Eleven Biotherapeutics, Inc. • September 21st, 2016 • Pharmaceutical preparations
It is my pleasure to offer you the position of Chief Medical Officer for Eleven Biotherapeutics, Inc. (“the Company” or “Eleven Bio”) reporting to Stephen Hurly, President and CEO. This letter agreement summarizes important details about your employment, should you accept this offer. This letter agreement shall be effective only upon the date of the closing (such closing date, the “Effective Date”) of the acquisition by the Company of Viventia Bio Inc. (“Viventia”) pursuant to a Share Purchase Agreement (the “Agreement”), by and among the Company, Viventia, the shareholders of Viventia named on the signature pages thereto and, for certain limited purposes, Clairmark Investments Ltd, pursuant to which Agreement, the Company will acquire all of the outstanding equity interests in Viventia and Viventia will become a wholly-owned subsidiary of the Company (the “Transaction”). If the Transaction does not occur by September 23, 2016, this letter agreement shall be null and void.
